+

Cookies on the Business Insider India website

Business Insider India has updated its Privacy and Cookie policy. We use cookies to ensure that we give you the better experience on our website. If you continue without changing your settings, we\'ll assume that you are happy to receive all cookies on the Business Insider India website. However, you can change your cookie setting at any time by clicking on our Cookie Policy at any time. You can also see our Privacy Policy.

Close
HomeNewslettersNextShare

Fabiflu, Covifor, Cipremi and other drugs approved or under trial for COVID-19 patients in India


  • Glenmark Pharmaceuticals on June 22 announced the launch of antiviral drug Favipiravir — under its brand name FabiFlu — for the treatment of mild to moderate COVID-19 patients.
  • Cipla and Hetero introduced the Remdesivir “the most promising candidate” for treating the novel coronavirus.
  • These drugs were originally designed to treat other diseases like any skin disease or arthritis but now their generic version is introduced to treat coronavirus patients.
There is some good news for Indians — medicines showing promising results to treat coronavirus. India’s pharmaceutical companies like Glenmark, Hetero Drugs, and Cipla have repurposed at least five drugs that might help treat coronavirus patients.


These drugs were originally designed to treat other diseases like any skin disease or arthritis but now their generic version is introduced to treat coronavirus patients. The news comes at a time when the novel coronavirus has infected over 4 lakh people in the country and killed over 15,000.

Advertisement

You are subscribed to notifications!
Looks like you've blocked notifications!